Article info
PDFClinical and epidemiological research
Concise report
Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomised controlled trial
- Correspondence to Professor B Fautrel, Pierre et Marie Curie University (Paris VI); Department of Rheumatology, Pitie Salpetriere Hospital, 83 boulevard de l’Hôpital, 75651 Paris cedex 13, France; bruno.fautrel{at}psl.aphp.fr
Citation
Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomised controlled trial
Publication history
- Accepted July 24, 2009
- First published September 9, 2009.
Online issue publication
November 02, 2019
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved.